dromlakhani Recommend low-dose GH replacement for cured acromegaly with GHD
STEP 1 — Gather Information
Confirm cured acromegaly (post‑surgical or post‑radiation, normal IGF‑1, no radiographic evidence of active disease). Document GHD via an approved GH stimulation test (insulin tolerance, glucagon, or GHRH‑arginine) per guideline. Screen for contraindications: active malignancy, uncontrolled diabetes, severe sleep apnea, intracranial hypertension, or pregnancy.
STEP 2 — Rule In / Rule Out
Is there documented GHD in a patient with cured acromegaly and no contraindications?
- Yes → proceed to STEP 3.
- No → do not initiate GH replacement; reassess if clinical suspicion changes.
STEP 3 — Classify or Stratify
Stratify by age to select starting dose range (per Table 5):
- Age < 60 years → start 0.2–0.4 mg/d.
- Age ≥ 60 years → start 0.1–0.2 mg/d.
STEP 4 — Decide
Prescribe low‑dose GH replacement at the age‑appropriate starting dose, administered subcutaneously nightly. Titrate by 0.1–0.2 mg/d every 6 weeks aiming to keep IGF‑1 below the upper limit of normal while monitoring for side effects (fluid retention, arthralgia, hyperglycemia). Continue long‑term with periodic IGF‑1, metabolic, and safety assessments.
Clinical Guardrails / Mimics / Pitfalls
Do not initiate GH if any contraindication exists (active neoplasm, uncontrolled diabetes, severe sleep apnea). Avoid over‑replacement; excess GH can cause insulin resistance, edema, and arthralgias. Monitor IGF‑1 regularly; if IGF‑1 exceeds normal range, reduce dose. Be aware that untreated central hypothyroidism may be unmasked when starting GH; assess thyroid function before and during therapy.
Concrete Clinical Example
A 58‑year‑old woman underwent transsphenoidal resection for acromegaly; postoperative IGF‑1 is normal, GH stimulation test peak is 3 ng/mL (consistent with GHD), and she has no contraindications. Per the algorithm, she receives a starting dose of 0.3 mg/d GH nightly, titrated to 0.5 mg/d after 6 weeks to maintain IGF‑1 just below the upper limit of normal, with no adverse effects noted at 3‑month follow‑up.
Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118